Original Articles

You have full text access to this OnlineOpen article

Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation

George K. K. Lau 102 Pokfulum Rd.^1,*,
Ming-Liang He²,
Daniel Y. T. Fong³,
Angeline Bartholomeusz⁴,
Wing-yan Au⁵,
Albert K. W. Lie⁵,
Stephen Locarnini⁴,
Raymond Liang⁵

Article first published online: 30 DEC 2003

DOI: 10.1053/jhep.2002.35068

Issue

Hepatology

Volume 36, Issue 3, pages 702–709, September 2002

Additional Information

How to Cite

Lau, G. K. K., He, M.-L., Fong, D. Y. T., Bartholomeusz, A., Au, W.-y., Lie, A. K. W., Locarnini, S. and Liang, R. (2002), Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology, 36: 702–709. doi: 10.1053/jhep.2002.35068

Author Information

¹
Division of Gastroenterology and Hepatology, University of Hong Kong, Hong Kong Special Administrative Region, China
²
Institute of Molecular Biology, University of Hong Kong, Hong Kong Special Administrative Region, China
³
Clinical Trials Centre, University of Hong Kong, Hong Kong Special Administrative Region, China
⁴
Victorian Infectious Diseases Reference Laboratory, Fairfield, Victoria, Australia
⁵
Division of Hematology, Department of Medicine, University of Hong Kong, Hong Kong Special Administrative Region, China

Email: George K. K. Lau 102 Pokfulum Rd. (gkklau@netvigator.com)

^*Hong Kong SAR, China. hyphen;28871, Alcalá de Henares, Spain. fax: (852) 28190694.

Publication History

Issue published online: 30 DEC 2003
Article first published online: 30 DEC 2003
Manuscript Accepted: 2 JUN 2002
Manuscript Received: 27 FEB 2002

Funded by

Cheng Si-yuan (China-International) Hepatitis Research Foundation (to the University of Hong Kong), China National 973 to G.K.K.L.. Grant Number: G 1999 054105
Kadoori Charitable Foundation (to R.L.)

ARTICLE TOOLS

Abstract
References
Cited By

Get PDF (132K)

References

1
Liang R, Lau GKK, Kwong YL. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J Clin Oncol 1999; 17:394–398.MEDLINE
2
Lau GKK. Hepatitis B infection in China. Clin Liver Dis 2001; 5:361–379.MEDLINE
- CrossRef,
- PubMed,
- CAS
3
Hoofnagle JH, Dusheiko GM, Schafer DF, Jones EA, Micetich KC, Young RC, Costa J. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 1982; 96:447–449.MEDLINE
4
Perrillo RP. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001; 120:1009–1022.MEDLINE
5
McMillan JS, Shaw T, Angus PW, Locarnini SA. Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro. Hepatology 1995; 22:36–43.MEDLINE
6
Lau GKK, Leung YH, Fong DYT, Au WY, Kwong YL, Lie A, Hou JH, et al. High HBV DNA viral load is the most significant risk factor for hepatitis B reactivation in hepatitis B surface antigen positive patients treated with autologous hematopoietic cell transplantation. Blood 2002; 99:2324–2330.MEDLINE
7
Bortin MM, Horowitz MM, Gale RP, Barrett AJ, Champlin RE, Dicke KA, Gluckman E, et al. Changing trends in allogeneic bone marrow transplantation for leukemia in the 1980s. JAMA 1992; 268:607–612.MEDLINE
8
Chen PM, Liu JH, Fan FS, Hsieh RK, Wei CH, Liu RS, Tzeng CH. Liver disease after bone marrow transplantation: the Taiwan experience. Transplantation 1995; 59:1139–1143.MEDLINE
9
Reed EC, Myerson D, Corey L, Meyers JD. Allogeneic marrow transplantation in patients positive for hepatitis B surface antigen. Blood 1991; 77:195–200.MEDLINE
10
Locasciulli A, Alberti A, de Bock R, Cordonnier C, Einsele H, Engelhard D, Grundy J, et al. Impact of liver disease and hepatitis infections on allogeneic bone marrow transplantation in Europe: a survey from the European Bone Marrow Transplantation (EBMT) Group: Infectious Diseases Working Party. Bone Marrow Transplant 1994; 14:833–837.MEDLINE
11
Ustun C, Koc H, Karayalcin S, Akyol G, Gurman G, Ilhan O, Akan H, et al. Hepatitis B virus infection in allogeneic bone marrow transplantation. Bone Marrow Transplant 1997; 20:289–296.MEDLINE
12
Martin BA, Rowe JM, Kouides PA, DiPersio JF. Hepatitis B reactivation following allogeneic bone marrow transplantation: a case report and review of the literature. Bone Marrow Transplant 1995; 15:145–148.MEDLINE
13
Dhedin N, Douvin C, Kuentz M, Saint Marc MF, Reman O, Rieux C, Bernaudin F, et al. Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc. Transplantation 1998; 66:616–619.MEDLINE
14
Caselitz M, Link H, Hein R, Maschek H, Boker K, Poliwoda H, Manns MP. Hepatitis B associated liver failure following bone marrow transplantation. J Hepatol 1997; 27:572–577.MEDLINE
15
Pariente EA, Goudeau A, Dubois F, Degott C, Gluckman E, Devergie A, Brechot C, et al. Fulminant hepatitis due to reactivation of chronic hepatitis B virus infection after allogeneic bone marrow transplantation. Dig Dis Sci 1988; 33:1185–1191.MEDLINE
16
Yoshiba M, Sekiyama K, Sugata F, Okamoto H, Yamamoto K, Yotsumoto S. Reactivation of precore mutant hepatitis B virus leading to fulminant hepatic failure following cytotoxic treatment. Dig Dis Sci 1992; 37:1253–1259.MEDLINE
17
Carman WF, Korula J, Wallace L, MacPhee R, Mimms L, Decker R. Fulminant reactivation of hepatitis B due to envelope protein mutant that escaped detection by monoclonal HBsAg ELISA. Lancet 1995; 3;345:1406–1407.
- CrossRef,
- Web of Science® Times Cited: 128
18
Lau JY, Bird GL, Gimson AE, Alexander GJ, Williams R. Treatment of HBV reactivation after withdrawal of immunosuppression. Lancet 1991; 337:802.MEDLINE
19
Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339:61–68.MEDLINE
20
Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341:1256–1263.MEDLINE
21
Main J, Brown JL, Howells C, Galassini R, Crossey M, Karayiannis P, Georgiou P, et al. A double blind, placebo-controlled study to assess the effect of famciclovir on viral replication in patients with chronic hepatitis B virus infection. J Viral Hepat 1996; 3:211–215.MEDLINE
Direct Link:
22
Trepo C, Jezek P, Atkinson G, Boon R, Young C. Famciclovir in chronic hepatitis B: results of a dose-finding study. J Hepatol 2000; 32:1011–1018.MEDLINE
23
de Man RA, Marcellin P, Habal F, Desmond P, Wright T, Rose T, Jurewicz R, et al. A randomized, placebo-controlled study to evaluate the efficacy of 12-month famciclovir treatment in patients with chronic hepatitis B e antigen-positive hepatitis B. Hepatology 2000; 32:413–417.MEDLINE
Direct Link:
24
Yeo W, Steinberg JL, Tam JS, Chan PK, Leung NW, Lam KC, Mok TS, et al. Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy. J Med Virol 1999; 59:263–269.MEDLINE
Direct Link:
25
Maguire CM, Crawford DH, Hourigan LF, Clouston AD, Walpole ET, Powell EE. Case report: lamivudine therapy for submassive hepatic necrosis due to reactivation of hepatitis B following chemotherapy. J Gastroenterol Hepatol 1999; 14:801–803.MEDLINE
Direct Link:
26
Clark FL, Drummond MW, Chambers S, Chapman BA, Patton WN. Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin's lymphoma. Ann Oncol 1998; 9:385–387.MEDLINE
27
Ahmed A, Keeffe EB. Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection. Am J Gastroenterol 1999; 94:249–251.MEDLINE
Direct Link:
28
Tang S, Ho SK, Moniri K, Lai KN, Chan TM. Efficacy of famciclovir in the treatment of lamivudine resistance related to an atypical hepatitis B virus mutant. Transplantation 2002; 15:148–151.
- CrossRef,
- Web of Science® Times Cited: 14
29
Steinberg JL, Yeo W, Zhong S, Chan JY, Tam JS, Chan PK, Leung NW, et al. Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: precore/core mutations may play an important role. J Med Virol 2000; 60:249–255.MEDLINE
Direct Link:
30
Lau GK, Liang R, Wu PC, Lee CK, Lim WL, Au WY. Use of famciclovir to prevent HBV reactivation in HBsAg-positive recipients after allogeneic bone marrow transplantation. J Hepatol 1998; 28:359–368.MEDLINE
31
McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 1984; 4:116–122.MEDLINE
Direct Link:
32
Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, Lerner KG, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18:295–304.MEDLINE
33
Stuyver LJ, Locarnini SA, Lok A, Richman DD, Carman WF, Dienstag JL, Sohinazi RF. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001; 33; 751–757.MEDLINE
Direct Link:
34
Delaney WE, Edwards R, Colledge D, Shaw T, Torresi J, Miller TG, Isom HC, et al. Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus. Antimicrob Agents Chemother 2001; 45:1705–1713.MEDLINE
35
Rossi G, Pelizzari A, Motta M, Puoti M. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol 2001; 115:58–62.MEDLINE
Direct Link:
36
Persico M, De Marino F, Russo GD, Morante A, Rotoli B, Torella R, De Renzo A. Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma. Blood 2002; 99:724–725.MEDLINE
37
Majluf-Cruz A, Luna-Castanos G, Trevino-Perez S, Santoscoy M, Nieto-Cisneros L. Lamivudine-induced pure red cell aplasia. Am J Hematol 2000; 65:189–191.MEDLINE
Direct Link:
38
Strasser SI, McDonald GB: Hepatitis viruses and hematopoietic cell transplantation: a guide to patient and donor management. Blood 1999; 93:1127–1136.MEDLINE
39
Lau GKK, Lok ASF, Liang RHS, Lai CL, Chiu EKW, Lau YL, Lam SK. Clearance of HBsAg after bone marrow transplantation: role of adoptive immunity transfer. Hepatology 1997; 25:1497–1501.MEDLINE
Direct Link:
40
Boni C, Bertoletti A, Penna A, Cavalli A, Pilli M, Urbani S, Scognamiglio P, et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998; 102:968–975.MEDLINE
41
Honkoop P, de Man RA, Niesters HGM, Zondervan PE, Schalm SW. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 2000; 32; 635–639.MEDLINE
Direct Link:
42
Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000—summary of a workshop. Gastroenterology 2001; 120:1828–1853.MEDLINE
43
Liaw YF, Chien RN, Yeh Ct, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999; 30; 567–572.MEDLINE
Direct Link:
44
Mutimer D, Feraz-Neto BH, Harrison R, O'Donnell K, Shaw J, Cane P, Pillay D. Acute liver graft failure due to emergence of lamivudine resistant hepatitis B virus: rapid resolution during treatment with adefovir. Gut 2001; 49:860–863.MEDLINE
45
Shaw T, Locarnini S. Combination chemotherapy for hepatitis B virus: the final solution? Hepatology 2000; 32:430–432.MEDLINE
Direct Link:
46
Lau GKK, Tsiang M, Hou J, et al. Combination therapy with lamivudine and famciclovir for Chronic hepatitis B infected Chinese: a viral dynamics study. Hepatology 2000; 32:394–399.MEDLINE
Direct Link:

Get PDF (132K)

JOURNAL TOOLS

JOURNAL MENU

FIND ISSUES

FIND ARTICLES

GET ACCESS

FOR CONTRIBUTORS

ABOUT THIS JOURNAL

SPECIAL FEATURES

Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation

Hepatology

How to Cite

Author Information

Publication History

Funded by

ARTICLE TOOLS

References

More content like this

JOURNAL TOOLS

JOURNAL MENU

FIND ISSUES

FIND ARTICLES

GET ACCESS

FOR CONTRIBUTORS

ABOUT THIS JOURNAL

SPECIAL FEATURES

Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation

Hepatology

How to Cite

Author Information

Publication History

Funded by

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

References

More content like this